Macrogenics (MGNX) Current Deferred Revenue (2012 - 2026)

Macrogenics (MGNX) has 15 years of Current Deferred Revenue data on file, last reported at $68.0 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $68.0 million, up 335.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $68.0 million (up 335.29% YoY), and the FY2025 annual result was $10.9 million, down 33.08% from the prior year.
• Current Deferred Revenue advanced to $68.0 million in Q1 2026 per MGNX's latest filing, from $10.9 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $100.0 million in Q1 2023 and troughed at $7.1 million in Q3 2022.
• A 5-year average of $23.7 million and a median of $16.3 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue surged 626.19% in 2022, then slumped 77.16% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $10.0 million in 2022, then jumped by 116.77% to $21.7 million in 2023, then retreated by 24.63% to $16.3 million in 2024, then sank by 33.08% to $10.9 million in 2025, then surged by 522.59% to $68.0 million in 2026.
• Business Quant data shows MGNX's Current Deferred Revenue at $68.0 million in Q1 2026, $10.9 million in Q4 2025, and $10.3 million in Q3 2025.